《大行》中金升科伦博泰生物(06990.HK)目标价至230元 TROP2 ADC获批上市期待商业化放量

阿斯达克财经
Dec 04, 2024

中金发表报告,科伦博泰生物(06990.HK) 公告核心产品芦康沙妥珠单抗在中国获批上市,用于治疗2L及以上三阴性乳腺癌,这是国内首个获批上市的国产TROP2 ADC。报告指,本次批准基于国内三期临床试验OptiTROP-Breast01的积极结果。根据2024年ASCO上公司披露的中期分析数据,与化疗相比sac-TMT在患者无进展生存期和总生存期方面均显示出具有显著统计学意义和临床意义的改善,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10